Instead of expanding at its New Jersey headquarters, Legend Biotech opened its new R&D center in Philadelphia. This strategic move aims to attract specialized scientific talent by deliberately locating in a key innovation hub for cell therapy, demonstrating a "go to the talent" growth strategy.

Dan Schmitt used his role as an Entrepreneur in Residence at Northwestern University to gain priority access to new technologies. This strategic position allowed him to secure the foundational asset for Actuate Therapeutics, directly bridging academic innovation with commercial enterprise.

CZI's Biohub model hinges on a simple principle: physically seating biologists and engineers from different institutions (Stanford, UCSF, Berkeley) together. This direct proximity fosters collaboration and creates hybrid experts, overcoming the institutional silos often reinforced by traditional grant-based funding.

For years, Actuate's CEO has shared progress with large pharma companies, not just for early deal-making, but to get critical feedback on their development plan. This helps them understand what data potential acquirers need to see to make a compelling offer later.

Responding to Wall Street pressure to de-risk, large pharmaceutical firms cut internal early-stage research. This led to an exodus of talent and the rise of contract research organizations (CROs), creating an infrastructure that, like cloud computing for tech, lowered the barrier for new biotech startups.

Winning a 'Golden Ticket' from a major pharma company like Servier provides more than just lab space. It acts as a powerful external validation of the science, which in turn helps the startup gain credibility to win additional awards and attract investment from other major players like Eli Lilly and Ono Pharma.

European firm Permira successfully entered the US not by just opening an office, but by relocating its top talent, empowering local decision-making, and accepting years of minimal activity to build relationships and market knowledge before scaling.

Exor is strategically entering the healthcare sector not through a large acquisition, but by taking significant minority stakes in companies like Philips and Institut Mérieux. This gives them a "front row seat" to learn the industry, build knowledge, and establish credibility for a long-term pivot.

To avoid the pitfalls of scale in R&D, Eli Lilly operates small, focused labs of 300-400 people. These 'internal biotechs' have mission focus and autonomy, while leveraging the parent company's scale for clinical trials and distribution.